Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl PatchNutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory BoardORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(
NASDAQNTRB)
NASDAQ:NTRBWNASDAQNTRBW)
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia
Nutriband Issues Letter to ShareholdersORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (
NASDAQNTRB)
NASDAQ: NTRBWNASDAQNTRBW)
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal TechnologyNutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4thORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.
Nutriband Inc. Announces Seven-for-Six Forward Stock SplitORLANDO, FL / ACCESSWIRE / July 27, 2022 / Nutriband Inc. (
NASDAQNTRB)
NASDAQ:NTRBWNASDAQNTRBW)
Nutriband Supports Update to CDC Opioid Prescribing GuidelinesNew proposed guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications
Nutriband Inc. to Present at the Emerging Growth Conference on May 25Nutriband Inc. Invites Individual and Institutional Investors As Well as Advisors and Analysts, To Attend Its Real-Time, Interactive Presentation at the Emerging Growth Conference
Nutriband Subsidiary Active Intelligence LLC Registers with FDA as a Medical Device Manufacturer for its AI Kinesiology Tape ProductClass 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC ORLANDO, FL / ACCESSWIRE / May 11, 2022 / Nutriband Inc. (
NASDAQNTRB)
NASDAQ:NTRBWNASDAQNTRBW)
Nutriband Inc. Reports Revenue Up 56% in Fiscal 2022 to a Record $1.4MOur newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
